Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA

Eisai (4523.T) and partner Biogen (BIIB.O) said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi.